The Hourly View for JNJ
Last Updated December 30, 2020, 06:07 GMT
At the time of this writing, Johnson & Johnson’s price is up $1 (0.65%) from the hour prior. This is the 2nd hour in a row Johnson & Johnson has seen its price head down. If you’re a trend trader, consider that the strongest clear trend on the hourly chart exists on the 100 hour timeframe. The moving averages on the hourly timeframe suggest a choppiness in price, as the are all in a mixed alignment — meaning the trend across timeframes is inconsistent, indicating a potential opportunity for rangebound traders.
Johnson & Johnson Daily price Recap
Johnson & Johnson closed the previous day up 0.62% ($0.95); this denotes the 3rd straight day it has gone up. The change in price came along side change in volume that was up 34.74% from previous day, but down 47.65% from the Tuesday of last week. Let’s take a look at the daily price chart of Johnson & Johnson.
Johnson & Johnson Technical Analysis
The first thing we should note is that Johnson & Johnson is now close to its 20 day moving averages, which may act as price barrier for the asset. Volatility for Johnson & Johnson has been contracting over the past two weeks relative to volatility over the past month. Whether volatility reverts will be something to watch. The clearest trend exists on the 30 day timeframe, which shows price moving up over that time. price action traders in particular will want to note that the 90 day period appears to show price forming a base; this could indicate that a support/resistance level is developing. For additional context, note that price has gone up 16 out of the past 30 days. As for those who trade off of candlesticks, we should note that we’re seeing pin bar pattern appearing here.
Overheard Around the Web
Over on StockTwits, here’s an example of what they’re saying about JNJ:
$MRNA $MRNA $(BNTX)
Bears, Shorts, Bsings they all screwed you for dumping your shares.
These two stocks are WAY UNDERVALUED !
The Revenue for these two companies are expected to be over $15B – $30B for year 2021.
This revenue is the FACT !!!! CONTRACTS !!!!! not an imaginary number !
The revenue supports MRNA at least $300/share
Now, you see? go check which bio pharms making $15B – $30B a year, check their market cap.
They had trolled you to dump your shares, so they could get them (BA)CK CHEAPER !
They all know BOTH (BNTX) and MRNA will be worth a lot more next year !
Buy these two stocks as they dip.
There won’t be no tough competition, Current production is not ENOUGH to cover the whole world, 7 BILLION POPULATION, even half of them gets vaccination, needs about 7 BILLION doses
$(AZN) $JNJ (DNA typed vaccine), let them come in next few months, still it is NOT ENOUGH at these current production rate !!!!